Vulcan Energy Resources

Phase A — Understand the business

Lens 1 · Company Overview

Vulcan Energy is building the world's first integrated, carbon-neutral lithium + renewable-energy business — its "Zero Carbon Lithium™" model — in the Upper Rhine Valley brine field straddling Germany and France. The mechanism is the whole thesis: it drills ~3,000 m into a hot, lithium-bearing geothermal brine, uses the co-produced geothermal heat to run the plant and sell renewable power/heat, and pulls lithium out of the same brine with adsorption-type Direct Lithium Extraction (A-DLE) — so the lithium is decarbonised because it is powered by the resource it comes from, and the brine is reinjected. Two products from one well.

The flagship is Phase One "Lionheart": target 24,000 tpa lithium hydroxide monohydrate (LHM) — enough for ~500,000 EV batteries a year — plus 275 GWh/yr renewable electricity and 560 GWh/yr heat, over an estimated 30-year life. First LHM production is scheduled for 2028 after a ~2.5-year build.

• Customers (lithium): fully sold out for the first five years under binding offtakes with Stellantis, Volkswagen, Renault, Umicore, LG Energy Solution, plus an 8-yr Glencore deal signed Oct 2025 for 36,000–44,000 t LHM. ~72% of planned output is under fixed- or floor-price contracts — real price-downside protection for a commodity name.
• Customers (energy): district-heating and industrial offtakers incl. EnergieSüdwest AG (Landau) and a renewable-heat deal with Energie Süd-West.
• Suppliers/partners: in-house VULSORB® sorbent (proprietary), NORAM (Canada) electrolysers, drilling contractors, and a BASF partnership (Nov 2024) to explore regional geothermal potential.
• Owners/operators: founder Francis Wedin (geologist, now investor-facing exec chair, ~7–8%), CEO Cris Moreno (since 2023), strategic holders Gina Rinehart / Hancock Prospecting (~6.5%) and Stellantis (~5.8%).

Plain terms: this is a regulated European infrastructure/chemicals build with a technology-risk core, dressed as a lithium miner. The bet is that a novel process works at commercial scale, on time, on budget — the offtake and funding are already de-risked.

Lens 2 · Supply Chain

Name-by-name map, upstream → Vulcan → downstream:

Upstream inputs

• Subsurface resource — Upper Rhine Graben geothermal brine (Vulcan's licences; "Europe's largest lithium deposit" per company).
• Drilling — production wells LSC-1 (5th) and LSC-2 (6th, to 3,000 m) drilled by contract rigs; wells are the single most important physical input (flow rate = tonnes).
• DLE sorbent — VULSORB®, produced in-house (vertical integration removes a key third-party dependency vs peers who buy off-the-shelf sorbent).
• Electrolysis — NORAM Electrolysis Systems (Canada): converting LiCl → LiOH at industrial scale — first anywhere in the battery chain.
• EPC / civils / turbines — ORC turbine + plant construction contractors (unnamed in public sources).

Vulcan (the conversion node)

• Wells → LEOP (Lithium Extraction Optimisation Plant, Landau) produces lithium chloride via A-DLE at >90% extraction efficiency → CLEOP (Central Lithium Electrolyser Optimisation Plant, Frankfurt-Höchst) refines to battery-quality LHM. First battery-quality LHM produced Jan 2025 — "first fully integrated, battery-quality LHM produced in Europe, raw material to final product".

Downstream

• Lithium → Stellantis, VW, Renault, Umicore, LGES, Glencore.
• Energy → EnergieSüdwest, Energie Süd-West, local district heating + grid.
• Financiers (the third leg of the chain for a capital project this size) — a 13-institution debt syndicate: EIB + 5 ECAs (Bpifrance AE, Denmark's EIFO, Export Finance Australia, Export Development Canada, SACE) + 7 commercial banks (ABN AMRO, BNP Paribas, ING, Kommunalkredit, Natixis CIB, OCBC, UniCredit); plus KfW and €204m German government grants.

Chokepoints / single-source dependencies: (1) reservoir productivity — if wells don't flow, nothing else matters; (2) A-DLE recovery at scale — pilot ≠ 24 ktpa; (3) NORAM electrolysis scale-up — unproven at this size anywhere; (4) single geography — one brine field, one jurisdiction (Germany), concentrated permitting/seismicity risk. This lens is the crux: the chain is short and elegant, but three of its four links have never operated together at commercial scale.

Lens 3 · Competitive Advantages (moats)

Ranked by durability:

1. The resource + first-mover position. Upper Rhine Graben is a large, hot, lithium-bearing brine with an existing geothermal industry — and Vulcan holds the licences and is years ahead of European peers on permitting, piloting and funding. Being the first to reach FID/financial close in European geothermal-lithium is itself a moat (capital and permitting are the barriers).
2. Vertical integration + dual revenue. Owning the geothermal energy means (a) the "zero-carbon" claim is structural not purchased, (b) a second, price-uncorrelated cash stream (heat/power), and (c) local stakeholder goodwill — district heating to German towns is permitting insurance in a region that has blocked projects before.
3. EU policy tailwind = a regulatory moat. Lionheart (and peers) are designated Strategic Projects under the EU Critical Raw Materials Act, which prioritises permitting and public funding for domestic, non-China supply. €204m grants + EIB/KfW/ECA debt is the moat made cash.
4. Offtake lock-in + strategic shareholders. Sold out 5 yrs, Stellantis on the register and the customer list, Rinehart validation. Switching a qualified battery-grade supplier is slow — once VW/LGES qualify Vulcan's LHM, that's sticky.
5. VULSORB IP — proprietary sorbent with claimed higher performance / lower water use. Real but the weakest moat: sorbent chemistry is a crowded, fast-moving field.

Bargaining power: genuinely two-sided. Offtakers need EU-domestic, low-carbon, CRMA-compliant lithium (tariff/ESG pressure on Chinese material) — that's Vulcan's leverage. But a pre-production developer needs their prepayments and their qualification sign-off more — so today the customers hold the whip. That flips only once Vulcan is a proven producer.

Honest moat verdict: the moats are real but conditional on execution. None of them protect a plant that doesn't run. This is a moat you earn at commissioning, not one you already own.

Lens 4 · Segments

No segments.csv on disk (web-only) — reporting segments per company disclosure are geographic: Germany (Lionheart, the core), Other European (France & Italy exploration/expansion), Australia (corporate). There is effectively one asset that matters (German Lionheart Phase One); everything else is optionality (Phase Two expansion, France/Italy licences).

By product, revenue today is legacy geothermal energy only — FY2023 revenue €33.8m, +138% YoY — from existing geothermal operations, not lithium. Lithium revenue is zero until 2028. So the "segment mix" story is prospective: post-2028, lithium becomes ~90%+ of revenue with renewable energy the ballast. Trend today is development spend accelerating, losses widening (FY2023 −€0.17/sh; 1H2024 −€0.11/sh vs −€0.10 1H2023) — normal and expected for a name in construction, but it means Lens 4 is a forecast, not a result.

---

Phase B — Measure performance

Pre-revenue: Lens 5 re-pointed from "earnings print" to latest result = funding + milestones; Lens 7 from "P/E comps" to development-stage peer set; multiples are n/a — pre-revenue where they can't be sourced.

Lens 5 · Latest Result — Financial Close + FID (the print that matters)

The material "result" is not an earnings beat — it's crossing the financing rubicon:

• Financial close reached 28 May 2026 on the €2,200m (A$3,929m) Phase One Lionheart package, and the board's Final Investment Decision (FID) was taken in Dec 2025 concurrent with the equity raise and start of on-site construction. This retires the single biggest historic overhang — will it ever be funded — with a definitive yes.
• Funding stack: €1,185m senior debt (13-institution syndicate incl. EIB + 5 ECAs + 7 banks), €529m equity, €204m German government grants, plus €364.3m existing liquidity (Q1 2026). (Note a headline discrepancy: one outlet framed the package as "$2.6bn" and another cited "$2.1bn debt / 13 institutions" — the authoritative EQS/Norton Rose figures are €2.2bn total / €1.185bn senior debt; I use those and flag the others as loose/partial headlines.)
• Balance sheet (Q1, 31 Mar 2026): cash €364.3m (incl €117.1m at-call) + €63.4m restricted/collateral; cash fell from €523m at Jan 1 — a €159m quarterly outflow (land, contractor milestones, ORC turbine), of which operating burn was only ~€6.4m. Post-close the project is fully funded through Phase One first production — dilution pressure structurally eases (Phase Two is a separate future ask).
• Equity raise mechanics / market reaction: the raise priced the institutional placement at A$4.00 — a 34% discount to the A$6.31 last-trade — A$710m institutional + ~A$366m retail (~A$1.0–1.1bn total). The tape's verdict on that dilution + FOAK-build reality: the stock fell from ~A$6+ to A$2.87 (10 Jul 2026), near the 52-wk low of A$2.79 (52-wk range A$2.79–7.52). The market is pricing execution/dilution pain, not the closed funding.
• Operational milestones in the same window: LSC-1 (5th well) flowed 105–125 L/s, above the ~84–94 L/s field-plan need; LSC-2 (6th well) reached 3,000 m TD, flow test due Q2 2026; first battery-quality LHM (Jan 2025).

Read-through: financially de-risked, technically still-proving, and the equity is being punished for the dilution rather than rewarded for the close. That gap is the setup.

Lens 6 · Management Commentary — sentiment trend

No earnings-call transcripts (web-only), but the narrative arc across investor updates is clear and worth tracking as sentiment:

• 2021 (peak-hype): "world-first zero-carbon lithium," aggressive resource/flow claims → market darling, stock to A$13.93 ATH (Sep 2021).
• Late-2021 → 2022 (defensive): post-J Capital short report, tone shifts to rebuttal, technical validation, and "de-risking." Focus: piloting, DFS.
• 2023–2024 (grind): lithium crash + capital-raise fatigue; language centres on cost discipline, staged capex, funding pathway, battery-quality qualification.
• 2025–2026 (delivery): the vocabulary flips to "financial close," "FID," "construction," "fully funded," "record drill results," "make-or-break flow test." Management stopped selling the dream and started reporting milestones — a healthier register, though governance questions were flagged around the 2026 AGM.

Sentiment trajectory: from promotional → embattled → operational. The recurring phrase now is execution; the thing they've stopped saying is anything speculative about Phase Two until Phase One flows. Constructive tonal shift, but the market wants proof (LSC-2 flow, first concrete milestones), not more language.

Lens 7 · Comps (development-stage DLE / lithium peer set)

Earnings multiples are n/a — pre-revenue for the DLE developers — comparing on stage, capacity, resource, funding, and project NPV instead. Multiples not fabricated.

Producing majors for scale/valuation reference (they have multiples, Vulcan doesn't yet): Albemarle (ALB), SQM, Arcadium/Pilbara — integrated producers trading on EV/EBITDA; a pre-revenue developer should trade at a deep discount to project NPV for execution risk, which Vulcan does: market cap A$1.38bn ≈ €0.83bn vs post-tax NPV €1.152bn → ~0.7x P/NPV. That discount is the execution/dilution/timing premium the market demands. Peer read: Vulcan is the most-funded, most-advanced, most-integrated name in DLE, and the only one at financial close — but also the one carrying the most capex and leverage.

Lens 8 · Stock-Price Catalysts (what actually moves it)

Moves >5% over the cycle and their triggers [all web]:

• 2019–Sep 2021 — the moonshot: backdoor-listed micro-cap → A$13.93 ATH (13 Sep 2021) on lithium mania + the zero-carbon narrative. Trigger: lithium sentiment + story.
• 26 Oct 2021 — J Capital short report ("god of empty promises"): trading halt, sharp drop. Trigger: technical-credibility attack.
• 2022–2024 — the lithium bear market: LHM/LCE prices collapsed from >$80k/t toward ~$10–15k/t; VUL fell with the complex (−45% in the year to Mar 2023, to ~A$5.78), one of the ASX's most-shorted stocks (~7%). Trigger: commodity price.
• Feb 2023 — DFS results (then €2.6bn post-tax NPV): supportive but overwhelmed by macro.
• 2024–2025 — funding drip + milestones: EIB €250m (2025), battery-quality LHM (Jan 2025), well results — each a step-change de-risk. Trigger: financing + technical proof.
• Dec 2025 — FID + A$4.00 dilutive raise: de-risk on funding, but the 34% placement discount and share-count jump drove the stock down. Trigger: dilution.
• 28 May 2026 — financial close: structurally huge; stock has not yet re-rated (still near 52-wk lows). Trigger not yet paid out.

Pattern: VUL trades on three things, roughly in this order — (1) the lithium price, (2) financing/dilution events, (3) discrete technical de-risking milestones. It does not trade on earnings (there are none). The tell for the coming 18 months: the market has fully priced the dilution and is discounting the closed funding — so the next LSC-2 flow test + on-time construction milestones, against a recovering lithium price, are the catalysts that could close the gap to the A$7.78 analyst target (+171%).

---

Phase C — Judge people & books

Lens 9 · Management

• Francis Wedin (founder, exec chair / investor-facing). Geologist; took Vulcan from a 2019 backdoor shell to a €2.2bn-financed, FID'd, first-of-its-kind European project with tier-1 auto/mining backers — a genuinely rare capital-formation and dealmaking track record. Holds ~7–8% (~A$65m) — meaningful skin in the game. The 2021 promotional excesses that drew the short report are on his ledger too.
• Cris Moreno (CEO, since 2023). Brought in as the professional operator to run delivery while Wedin moved to strategy/capital — the textbook founder→operator handoff a construction-phase company needs. Execution credibility is now being tested in real time.
• Strategic holders: Hancock Prospecting / Gina Rinehart ~6.5% (2nd largest — though trimmed from 7.51% to 6.49% into 2025, a mild negative tell) and Stellantis ~5.8% (customer + shareholder, extended supply to 2035). Rinehart + a global automaker on the register is strong third-party validation.
• Capital-allocation history: relentless equity issuance — 477.9m shares today after serial raises — appropriate (there is no other way to fund FOAK capex without over-levering), but real, ongoing dilution. No dividends/buybacks (correct for the stage). The €1.185bn debt now adds leverage that must be serviced from first cashflow.
• Founder-vs-professional archetype: founder-led visionary + hired operator — the right combination for the build phase, provided the operator delivers. Red flags: early promotional history (J Capital); governance questions flagged at the 2026 AGM; a major holder trimming. None disqualifying; all worth monitoring.

Lens 10 · Forensic Red Flags

Pre-revenue developer — the forensic lens re-points from revenue-recognition games to development-stage accounting and going-concern:

• Capitalised development costs — the standard pre-revenue watch item: how much spend is capitalised to the asset vs expensed. Impairment risk if the project economics deteriorate (they already halved once — see below). Unverifiable in detail without the filed accounts (not on disk); flag for the annual report.
• Going concern — historically the existential question; materially mitigated post-financial-close (fully funded through Phase One first production). Pre-2026 accounts likely carried going-concern language given the burn vs cash; now retired for Phase One.
• Economics deterioration (the real red flag): post-tax NPV fell from €2.6bn (Feb 2023 DFS) to €1.152bn (Dec 2025) and opex/C1 improved to €3,588/t while capex held ~€1.476bn — the NPV cut is the lithium-price reset, not a cost blowout, but it shows how sensitive the equity value is to price. Contingency was raised 10%→15% — prudent, but an admission of build-cost uncertainty.
• SBC / dilution — heavy share issuance flatters nothing here (no non-GAAP to game) but steadily dilutes per-share value; watch option/performance-rights grants.
• Restricted cash / guarantees — €63.4m tied up as collateral; normal for project finance but reduces free liquidity.

Regulatory findings (required):

• SEC (EDGAR LR + AAER): none — Vulcan has no CIK and is not an SEC filer; no EDGAR enforcement search is possible.
• Non-SEC enforcement (web search — FTC/DOJ/EU/consent-decree/fine/penalty): no material regulatory enforcement actions found against Vulcan Energy Resources as of 2026-07. The most consequential adversarial event remains the 2021 J Capital short report — an activist-research allegation, not a regulatory action; several of its central technical claims (flow rate "realistically ~70 L/s," DLE "will halve output") have since been contradicted by actual well results (105–125 L/s) and battery-quality LHM production.
• Item 3 / legal proceedings: no company 10-K on disk (ASX filer); no material litigation surfaced in web search.
• EU designation (positive): Lionheart is an EU Critical Raw Materials Act Strategic Project — a regulatory tailwind, not a finding.
• Net: No material regulatory or legal findings — verified via SEC EDGAR EFTS (no CIK), web enforcement search, and public disclosure review as of 2026-07-10. The standing risks are technical/FOAK and permitting/seismicity (geothermal in populated Germany), not enforcement.

---

Phase D — Project & stress-test

Lens 11 · Forward Projection (path-to-cashflow, not EPS)

EPS for the next three fiscal years is n/a — pre-revenue; the company will run construction losses through ~2028. No forecast.ts logged (unattended breadth mode + genuinely no committed base case pre-first-flow). Instead, the honest projection is path-to-first-cashflow and steady-state Phase One economics:

• Timeline: build 2026 → first LHM 2028 → ramp to 24 ktpa nameplate → 30-yr life. No revenue inflection until 2028; equity is a 2028-cashflow option funded through close.
• Steady-state Phase One revenue: 24,000 t LHM × LHM price:
• Bear ($15k/t): ~$360m lithium
• Base ($20k/t, ≈ current 2026 spot ~$19.5–25k): ~$480m lithium
• Bull ($28k/t): ~$670m lithium
• + renewable energy: 275 GWh power ×€80/MWh ≈ €22m + 560 GWh heat ×€40/MWh ≈ €22m → ~€45m/yr energy revenue × illustrative European tariffs].
• Steady-state cash margin: C1 opex €3,588/t (≈$3,900/t) → cash margin per tonne ≈ price − ~$3,900. At base $20k/t: ~$16,100/t × 24,000 ≈ ~$385m gross cash margin, less sustaining capex/SG&A → EBITDA very roughly €250–330m/yr at $20k/t.
• Illustrative steady-state net income: EBITDA ~€300m − D&A ~€49m (€1.476bn ÷ 30y) − interest ~€55–60m (€1.185bn × ~5%) − ~28% German tax ≈ ~€135–160m net → ~€0.28–0.33/sh on 478m shares (pre further dilution) ≈ A$0.46–0.55/sh. Against A$2.87 that is a ~5–6x multiple on 2028+, at-nameplate, base-price earnings — cheap if everything runs, which is the whole "if."
• Project value anchor: company post-tax NPV €1.152bn @ 8% (Dec 2025), post-tax IRR 13.7% unlevered / 16.6% levered. The 13.7% unlevered post-tax IRR is adequate, not spectacular for a FOAK single-asset — the equity return case leans on leverage (16.6%) and lithium-price upside.

Base call: funded, sold out, ~0.7x P/NPV, lithium recovering — a genuinely improved risk/reward, but the value is 3 years out and execution-gated. Not a forecast worth Brier-logging until LSC-2 flow + early construction confirm the base case.

Lens 12 · Bull vs Bear

Bull. The one thing that repeatedly nearly killed Vulcan — funding — is retired: €2.2bn closed, FID taken, fully funded to first production, vetted by 13 institutions incl. EIB + five sovereign ECAs (that is enormous third-party due-diligence validation). It is sold out with ~72% price-protected, backed by Stellantis and Rinehart, sitting on Europe's largest lithium brine, with a dual (uncorrelated) revenue stream and an EU-policy moat (CRMA strategic project, domestic non-China supply). The 2021 short thesis on flow rates has been empirically beaten (105–125 L/s). Lithium is recovering (Fastmarkets lifted 2026 LCE to $23.8/kg from $17.4/kg). And the stock trades near 52-wk lows at ~0.7x post-tax NPV with a A$7.78 consensus target (+171%). If Phase One simply works on schedule, this re-rates hard.

Bear. It is a single-asset, first-of-its-kind project: no geothermal-lithium plant has ever reached commercial production anywhere, and Vulcan is scaling A-DLE and NORAM electrolysis and a 24 ktpa integrated flowsheet simultaneously, for the first time. €1.476bn capex on a A$1.38bn company means the build is the equity — a cost blowout or 12-month slip is existential, and it now carries €1.185bn of debt to service. The post-tax unlevered IRR is only ~13.7%, so there's little cushion if opex/capex drift or lithium relapses (prices swing 30–45%/quarter). First cashflow is 2028 — years of execution risk with zero lithium revenue and continued dilution risk for Phase Two.

Pre-mortem (it's Jan 2028 and the thesis broke): the most likely failure paths — LSC-2 or subsequent wells under-deliver flow/temperature, or A-DLE recovery/uptime at 24 ktpa lands below the >90% pilot figure, or NORAM electrolysis scale-up stumbles, or capex overruns / construction slips past 2028, and/or lithium prices roll back over while fixed costs and interest accrue — any one of which forces a dilutive raise at a low price and craters the equity.

Are multiples too high? No — at ~0.7x post-tax NPV the equity is discounted for exactly these risks. The debate isn't valuation, it's execution probability.

Contrarian view (what the market is refusing to see): the market is still trading Vulcan as the perpetual promise-machine of 2021–24 and has not repriced the fact that financial close fundamentally changed the risk distribution — a project that 13 institutions and 5 sovereign ECAs underwrote to construction is a different security than a pre-FID story stock, yet it sits at 52-wk lows. The mispricing, if there is one, is time-and-sentiment, not thesis.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case:

• Concentration is total. One brine field, one country, one unproven flowsheet, ~90% of future revenue from a single product that has never been produced there at scale. There is no diversification to absorb a technical miss.
• The moat may be thinner than it looks. The "green premium" is the load-bearing assumption — but if cheap conventional brine (South America), African spodumene, and Chinese conversion keep LHM at $12–15k/t, a decarbonised European tonne with a 13.7% IRR has little pricing power; ESG buyers rarely pay a durable double-digit premium when the cheaper molecule is chemically identical. The most dangerous competitors bulls underrate aren't the other DLE juniors — they're incumbent low-cost supply + Chinese refiners setting the marginal price.
• FOAK risk is the whole company. "Pilot achieved >90%" is not "commercial plant runs at >90% uptime for 30 years." Every first-of-a-kind process plant in history has taken longer and cost more than the DFS said. The contingency bump (10%→15%) is management quietly conceding this.
• Capital allocation = dilution machine. 478m shares and counting; the A$4.00 placement at a 34% discount shows the equity is a price-taker when it needs cash — and Phase Two will need more.
• What must hold for A$2.87, let alone A$7.78: flow rates and DLE recovery and electrolysis scale-up and on-time/on-budget construction and a firm lithium price — all at once. Miss flow or recovery by 20–30% and the NPV (already halved to €1.152bn) collapses toward or below the capex, wiping the equity cushion.
• Single scenario that permanently impairs: LSC-2 (and confirmation wells) flow materially below plan, revealing the reservoir can't sustain 24 ktpa — the resource assumption fails, the plant is stranded, and the debt sits ahead of equity. Plausibility: lowered but not eliminated by LSC-1's strong 105–125 L/s — the Q2-2026 LSC-2 flow test is precisely the make-or-break data point.

Lens 14 · Fifteen Questions for the CEO (ordered by information value)

1. LSC-2 flow test: what sustained flow rate and temperature did it deliver, and does the field average across all production wells still support 24 ktpa at nameplate for 30 years?
2. At commercial scale, what A-DLE lithium recovery and plant uptime are you underwriting in the financed model — and how far below the >90% pilot figure can you go before Phase One economics break?
3. Walk me through capex contingency and the guaranteed/lump-sum content of the EPC contracts: how much of the €1.476bn is fixed-price vs exposed to overrun, and what's the realistic P50 vs P90 completion cost and date?
4. The NORAM electrolysis deployment is a first at this scale anywhere — what is the fallback if it underperforms, and is there a proven alternative path to battery-grade LHM?
5. What long-term LHM price underpins the €1.152bn NPV and the debt sizing, and at what price does the levered project stop covering its debt service?
6. Of the €1.185bn debt, what are the covenants, DSCR triggers, and completion guarantees, and what equity backstop do lenders require if construction slips?
7. On the 72% price-protected offtake — what are the actual floor prices, and how much volume is truly fixed vs indexed with a floor?
8. What is the realistic first-LHM date and ramp curve to nameplate, and what's the cash-flow bridge (and any further equity need) between now and steady-state?
9. How real and how large is the renewable-energy revenue at Phase One, and is it contracted at fixed tariffs or merchant-exposed?
10. What permitting, seismicity, and community risks remain for the production wells and reinjection, given prior local opposition to geothermal in the region?
11. Given Phase Two ambitions, what's the funding plan — and can you commit to no further equity dilution until Phase One is cash-generative?
12. How do you defend a 13.7% unlevered IRR against low-cost conventional/Chinese supply — where is the durable pricing power for "green" European lithium?
13. What did the 2026 AGM governance questions concern, and what board/controls changes have you made?
14. What is Hancock/Rinehart's intention with its stake after trimming to 6.49%, and is Stellantis committed beyond its current holding and offtake?
15. Name the single most likely reason Lionheart misses its 2028 production target — and what leading indicator would tell shareholders first?

---